• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds are described of the formula <IMAGE> in which R1 is COOR5, CONHR5, cyano, 5-tetrazolyl or R6, where R5 is hydrogen or C1-8 alkyl and R6 is phenyl or naphthyl, the phenyl or naphthyl group being optionally substituted by one or more group selected from halogen, C1-6 alkyl, C1-4 alkoxy, hydroxy, benzyloxy, nitro, trifluoromethyl, carboxyl, C1-4 alkylsulphinyl, C1-4 alkylsulphonyl, N(R5)2, NHCOR5 and SR5; R2 is R6 or -CH=CH-R6 when R1 is COOR5, CONHR5, cyano or 5-tetrazolyl, or R2 is -CH=CH-R6 when R1 is R6; R3 is hydrogen, C1-6 alkyl, halogen, hydroxy or -OCH2R6; and R4 is hydrogen, C1-6 alkyl or halogen; and salts thereof. The compounds have pharmaceutical properties and in particular are useful in the treatment of immediate hypersensitivity conditions such as asthma.
    公开号:SU1083909A3
    申请号:SU813254246
    申请日:1981-03-10
    公开日:1984-03-30
    发明作者:Питер Кларк Барри；Джеймс Росс Вильям；Тодд Алек
    申请人:Лилли Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new compounds of 6-substituted pyranone derivatives of the general formula cn-O.R RHC vn-VQ-, where R is the COOR group, where R is water or lower alkyl; or R-phenyl unsubstituted or substituted by halogen or lower alkoxy; R is phenyl, unsubstituted or substituted by halogen atom, hydroxy group, lower alkoxy group, lower alkylsulfonyl group, nitro group, trifluoromethyl, - SR or -HMCOR group, provided that when. -pheny, then R is not phenyl or 4-meth syphenyl. These compounds have useful biologically active properties and have a wide range of their use as pharmaceuticals, especially in the treatment of diseases associated with an immediate hypersensitive reaction. A known method for producing 2-styrylchromone by reacting 2-methylchromone with an aromatic aldehyde in the presence of base 1J. The purpose of the invention is to obtain new compounds: 6-substituted derivatives, pyranone of general formula 1, possessing pharmacological activity. This goal is achieved by the fact that, according to the method, the NTO pyranone of the general formula HjC-OR, where R has the indicated values, reacts with an aldehyde of the formula, where R has the indicated values, in the presence of a base at a temperature of 20 ° C to the boiling point of the reaction mixture. The compounds of Formula I have been found to be suitable for the prophylaxis and treatment of diseases caused by an immediate hypersensitive reaction, including asthma, and for the relief of an asthmatic status. They have low toxicity. This activity is established on guinea pigs, the wire experiment is either according to the incised lung method of the guinea pigs described by Mongar and Schild or Brokleharst or by the Herksmeyer method. More than 15% inhibition of mediator secretion was shown in guinea pigs tested on light. In the experiments of Gerksmeyer, based on allergic bronchospasm caused in guinea pigs and having a close resemblance to an asthma attack in humans, it was found that the proposed compounds have activity in doses ranging from 25 to 200 mg / kg. The compounds of formula 1 can be used in accordance with various treatment regimens, but are very effective when administered orally. Thus, the compounds of the formula can be administered through the mouth or into the rectum, topical or mini gastrointestinal tract, for example, by injection, which are usually used in the form of pharmaceutical compositions. Such compositions are prepared in a manner well known in pharmaceutical practice. They are usually included from at least one active compound in combination with a pharmaceutically acceptable carrier. In preparing the compositions, the active ingredient is usually mixed with a carrier or diluted by a carrier, or introduced into a carrier, which may be in the form of capsules, paper or other container. When the carrier serves as a diluent, it can be a solid, semi-solid, or liquid substance that plays the role of a filler, binder, or medium for the active ingredient. Thus, the compositions may be in the form of tablets, - pellets, capsules, elixirs,. Suspensions, aerosols in the form of solid materials or in a liquid medium, ointments containing, for example, up to 10 wt.% - the active component, solid or soft gelatinous. capsules, suppositories, injectable suspensions and sterile packaged powders. Examples of acceptable carriers include milk sugar, grape sugar, cane sugar, sorbitol, mannitol, starches, gum arabic, calcium phosphate, alginates, tragacanth, gelatin, syrup, methylcellulose, methyl and propyl oxy benzoate, talc, magnesium stearate or mineral oil. The composition may have a formulation that provides a quick, long or delayed release of the active ingredient after administering the composition to the patient. The compositions are formulated in unit dosage forms, each dose containing 5-500 mg, usually 25-200 mg of the active ingredient. The expression unit dosage form means physically discrete units suitable for a single dosage to a human or animal, each unit containing predetermined amounts of active material necessary to achieve the desired therapeutic effect, in combination with an acceptable pharmaceutical carrier.
    The active compounds are effective over a wide dosage range, for example, daily dosages are usually 0.5-300 mg / kg and in the treatment of an adult patient, preferably 5-100 mg / kg. However, it should be borne in mind that the amount of compound administered will be determined by the patient, i.e. its condition, type of compound and treatment regimen adopted.
    Example. (4-chlorophenyl-ethenyl J-b-phenyl-4H-pyran-4-one 3.7 g 2-methyl-b-phenyl-4H-pcran-4-one
    dissolved in a solution of sodium ethylate prepared by dissolving 0.46 g of sodium in 50 ml of ethanol. A solution of 5.6 g of 4-chlorobenzaldehyde in 50 ml of ethanol is added and the mixture is stirred at room temperature for 24 hours. The resulting solid is recrystallized from ethanol to give the title compound with mp. 169-171p.
    Example 2-6. Analogously to Example 1, the compounds of formula 1 below are obtained.
    The data of these examples are presented in table. one.
    Table
    Example 7. 4-G2- {4nExo-6-phenyl-4H-pyran-2-yl-ethenyl-benzoic acid. Prepare a solution of sodium ethylate by dissolving, 0 g of sodium in 75 ml of ethanol. 3.7 g of 2-methyl-6-phenyl-4H-pyran-4-one and 3.0 g of 4-carboxyben-3 aldehyde are added to the stirred solution and the mixture is kept at reflux for an hour, cooled and acidified with 2M salt Acidic acid (25 ml). The obtained solid is recrystallized from acetic acid and then from dimethylformamide-water. A pale yellow target compound with mp. above . Example (4-hydroxyphenyl ethenylZ-6-phenyl-4H-pyran-4-one. The ether linkage in 2-H2- (4-methoxyphenyl) -ethenyl-6phenyl-4H-pyran-4-6a is cleaved by boron borobromide, as a result The product is obtained as an orange needle-like crystal with a melting point of 98-20 C. Example 9 (4-acetamidophenyl) -ethenyl-6-phenyl-4H-pyran-4-one To boiling with 8.5 g of (4-nitrophenyl) -ethenyl} -6-phenyl-4I-pyran-4-one and iron powder (4.5 g) in 80 ml of ethanol and 20 ml of water are added to the suspension under reflux. The solution is added with stirring. 0.2 ml of concentrated hydrochloric acid in 20 ml of ethanol. The stirred mixture is boiled. under reflux for 5 hours, another 0.2 ml of concentrated hydrochloric acid is added after 2 h. The hot mixture is filtered and the filtrate is evaporated in vacuo. The solid residue is crystallized from chloroform-petroleum ether 60-80 C. The result is 2-С2- (4-aminophenyl) -ethenyl 1-6-phenyl-4H-pyran-4-one with a mp of 92-1§4 ° C. A stirred suspension of 2.3 g of the compound in 0.75 ml of acetic angldrid and 50 ml of toluene is refluxed for an hour. The mixture is cooled and the solid is crystallized from ethanol. The result is the target product with so pl. C (with decomposition). Example ib. (4-methylaulfonylphenyl | -ethenyl-6-3 | enyl-4H-pyran-4-one. A solution of 2.8 g of 2-1; 2- (4-methylthiophenyl | -ethenyl J-6) is stirred at room temperature for 2 h. -phenyl-4H-pyran-4-bna and 3.6 g of m-chloroperoxybenoic acid in 45 ml of ethanol-free chloroform.The resulting white solid is filtered off and the filtrate is washed with sodium bicarbonate solution, dried and evaporated. The residue is crystallized from ethanol chloroform. get the target product with so pl./ 239-24 ° C PRI me R 11. 4-Oxo-6- (2-phenyl ethenyl) -4H-pyran-2-carboxylic acid. K. stir andto a cooled solution of sodium ethylate prepared by dissolving 3.4 g of sodium in 150 ml of ethanol, a solution of 49 g of 2-methyl-2- (2-oxopropyl) -l, 3-dioxanol and 55 ml of diethyl oxalate in 50 ml of ethanol. The solution is stirred for 5 hours at room temperature, then acidified with 200 ml of 5M hydrochloric acid and further stirred for 1 hour. The mixture is diluted with 800 ml of water and extracted with ethyl acetate, the extracts are dried and evaporated, and the residue is stirred. distilled under vacuum (b.p. 110-120 ° C. At 0.2 mm), 53.8 g of distillate is crystallized from sulfuric petroleum ether 40-bO ° C. As a result, b-methyl-4-oxo-4H-pyran-2-carboxylic acid ethyl ester is obtained with m.p. 35-38C. A solution of 3.6 g of ester in. 100 ml of ethanol is added to a solution of sodium ethylate prepared by dissolving 1.0 g of sodium in 100 ml of ethanol. 2.45 ml of benzaldehyde is added, and the mixture is stirred at 80-90 ° C for one hour with stirring, then cooled, diluted with water (800 ml) and washed with sulfuric acid. The aqueous phase is acidified with 2M hydrochloric acid and extracted with ethyl acetate. The extract is dried and evaporated. The solid residue is recrystallized from dimethylformamide-water and get the target product with so pl.227228 with (with decomposition), Example 12. (4-methoxyphenyl) ethenyl-4-oxo-4H-pyran-2-carboxylic acid . The title compound was prepared as in Example 11. The melting point of the product was 232-234 ° C (with decomposition). Example 13. Preparing tablets containing mg: Active ingredient 50 Starch -200. Milk sugar 200 Polyvinylpyrrolidone (10% aqueous solution) 20 Sodium starch glycolate 20 Magnesium stearate 10 Starch, milk sugar and the active component are sieved through sieves and mixed thoroughly. A solution of polyvinylpyrrolidone is mixed with the resulting mixture, and passed through a 12 mesh sieve according to British Standard. The resulting granules are dried at about 55 ° C. and passed through a 16 mesh screen. Magnesium stearate and Sodium starch glycolate, previously passed through a 60 mesh sieve, are added to the granules. The mixture, after mixing, is compressed into tablets on a tabletting machine, each tablet of 500 mg. Example 14: Prepare capsules containing, mg: Active ingredient 50 Starch42 Milk sugar 45 Stearate. Magnes 3 Milk sugar, starch, magnesium stoarate and. the active component is passed through a 44 mesh screen and this composition fills 140 mg hard gelatin capsules each. Example 15. Preparing suppositories containing, mg: Active ingredient .50 Glycerols of saturated fatty acids Up to 2000, the active ingredient is passed through 60 mesh sieves and suspended in glycerides of saturated fatty acids that have previously been melted to a minimum amount of heat. Then the mixture is poured into forms in the amount of 2 g per candle and cooled. The test results showed that the compounds of Formula 1 are active when conducting a test with an incised guinea pig lung, which is an in vitro test commonly used to determine antiallergic activity. This test involves directly determining the amount of a slowly reacting substance at. anaphylaxis {MRV-AI, formed in response to a control infection. MRI-A has been shown to be expelled by the lungs of a person with asthma. Presented in table. 2, the data reflect a decrease in the formation of MPB-A after administration of solutions containing 10 g / ml of test compounds. It is not known that any compounds, similar to chemical structure, have antiallergic activity. Table 2
    Ph
    Ph
    Uciph
    ItCHjO
    Ph
    Ph
    Ph
    COOH
    COOH
    COOH
    COOCjHj
    Ph-phenyl,
    8 Pro9E {Table 2 .2
    1083909
    39
    44
    sixteen
    47
    47
    17
    h
    52
    thirty
    28
    42
    77
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING 6-SUBSTITUTED PYRANONE DERIVATIVES of the general formula where 82 “is a group of COOR 3 ;
    R 3 is hydrogen or lower alkyl, or R 1 is phenyl, unsubstituted or substituted with halogen or lower alkoxy;
    R 2 is phenyl unsubstituted or substituted by halogen, hydroxy, lower alkoxy, lower alkylsulfonyl, nitro, trifluoromethyl, -SR 3 or - HNCOR 3 , provided that when R 1 is phenyl or 4-methoxyphenyl, R 2 'is not phenyl or 4-methoxyphenyl, about t l region where R 1 ichimy that the general formula
    O has the indicated values and is subject to interaction with the aldehyde of the formula n , R 2 CHO, where R z has the indicated meanings (in the presence of basic at a temperature of from 20 ° C to the boiling point of the reaction mixture |
    类似技术:
    公开号 | 公开日 | 专利标题
    CA1087205A|1980-10-07|2-amino-3-|benzoylphenylacetic acids, estersand metal salts thereof
    US4238492A|1980-12-09|Phenoxyalkylcarboxylic acids
    US3484445A|1969-12-16|Derivatives of chromone-2-carboxylic acid
    US3517051A|1970-06-23|Phenoxy substituted phenylacetic acids
    US4113871A|1978-09-12|Hypoglycemically and hypolipidemically active derivatives of phenyl-alkane-carboxylic acids
    SU976850A3|1982-11-23|Method of producing derivatives of 5-substituted gamma-pyrones
    US4028404A|1977-06-07|Acetic acid derivatives
    SU1083909A3|1984-03-30|Process for preparing 6-substituted derivatives of pyranone
    IL23152A|1969-06-25|Aryl-substituted alkanoic acids
    US4526894A|1985-07-02|Pharmaceutically active 4-hydroxy-3-benzoyl-2-quinolone derivatives
    US5399584A|1995-03-21|Use of flavone derivatives for gastroprotection
    US20020068758A1|2002-06-06|Novel orally active iron | chelators
    US5185370A|1993-02-09|Substituted β-diketones and their use
    US4247706A|1981-01-27|Dibenzothiepin derivatives and a process for producing the same
    US4950818A|1990-08-21|Method for treating ulcer
    US3655743A|1972-04-11|Substituted 4 - biphenyl-4-hydroxy crotonic acids and salts thereof
    US4500731A|1985-02-19|Derivatives of 4-phenyl-4-oxobuten-2-oic acid, pharmaceutical compositions containing them, and therapeutic uses for them
    US4545993A|1985-10-08|1,2-Benzopyran-6-yl acetic acid compound and pharmaceutical compositions containing said compounds
    JPH07121940B2|1995-12-25|Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
    US4176194A|1979-11-27|Oxyalkanoic acid derivatives
    US4205087A|1980-05-27|Acetic acid derivatives
    US4116972A|1978-09-26|Anti-inflammatory 1-oxo-isoindoline derivatives and processes for their preparation
    US3963758A|1976-06-15|2-|phenyl acetic acids
    US4558046A|1985-12-10|Substituted carboxy-thiazolo [3,2-a] pyrimidine derivatives and process for their preparation
    US4269848A|1981-05-26|5-Substituted indan-2-carboxylic acid and functional derivatives
    同族专利:
    公开号 | 公开日
    AR224149A1|1981-10-30|
    AR226126A1|1982-05-31|
    SE8002514L|1980-10-06|
    FR2493147A1|1982-05-07|
    YU91980A|1983-02-28|
    RO80248A|1982-12-06|
    ES8104267A1|1981-04-01|
    IL59747D0|1980-06-30|
    AT371456B|1983-06-27|
    IE49658B1|1985-11-13|
    GB8312569D0|1983-06-08|
    AR224318A1|1981-11-13|
    GR67747B|1981-09-16|
    FI801019A|1980-10-06|
    DK142080A|1980-10-06|
    CS222198B2|1983-05-27|
    CS222197B2|1983-05-27|
    GB2123813A|1984-02-08|
    PL223228A1|1981-01-30|
    DE3012584A1|1980-10-16|
    HU182115B|1983-12-28|
    CH645370A5|1984-09-28|
    FR2493147B1|1985-02-15|
    PH16517A|1983-11-08|
    CA1142526A|1983-03-08|
    IE800670L|1980-10-05|
    RO84583A|1984-07-17|
    ZA801978B|1981-09-30|
    GB2047698A|1980-12-03|
    GB2123813B|1984-07-18|
    US4304728A|1981-12-08|
    DD150001A5|1981-08-12|
    PL123812B1|1982-11-30|
    RO84586B|1984-09-30|
    IL59747A|1983-12-30|
    CS222199B2|1983-05-27|
    AR226127A1|1982-05-31|
    AU536369B2|1984-05-03|
    JPS55133375A|1980-10-17|
    RO84583B|1984-09-30|
    LU82335A1|1981-12-02|
    FR2453169A1|1980-10-31|
    AU5703280A|1980-10-09|
    PL123813B1|1982-11-30|
    CS222186B2|1983-05-27|
    FR2453169B1|1985-03-08|
    BE882643A|1980-10-03|
    PL123699B1|1982-11-30|
    US4448787A|1984-05-15|
    ES490121A0|1981-04-01|
    PT71049A|1980-05-01|
    IT8048347D0|1980-04-04|
    RO84586A|1984-07-17|
    NZ193344A|1983-06-14|
    IT1143085B|1986-10-22|
    NL8002024A|1980-10-07|
    US4471129A|1984-09-11|
    GB2047698B|1983-10-19|
    PL123811B1|1982-11-30|
    ATA181980A|1982-11-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4065290A|1975-07-03|1977-12-27|Eli Lilly And Company|Herbicidal β-phenyl-4-piperidinones|
    US4060533A|1976-06-25|1977-11-29|Sandoz, Inc.|Pyranone carboxamides|US4644071A|1984-07-11|1987-02-17|G. D. Searle & Co.|Aralkoxy and aryloxyalkoxy kojic acid derivatives|
    DK59688A|1987-03-20|1988-09-21|Hoffmann La Roche|STYRYLKETONER|
    KR20000064811A|1996-04-26|2000-11-06|스즈키 다다시|Preparation method of tetrahydroindoligin derivative|
    TW587079B|1998-09-25|2004-05-11|Almirall Prodesfarma Ag|2-phenylpyran-4-one derivatives|
    PE20011333A1|2000-03-16|2002-01-16|Almirall Prodesfarma Ag|DERIVATIVES OF 2-FENYLPYRAN-4-ONA AS INHIBITORS OF CYCLOOXYGENASE 2|
    WO2001096283A2|2000-06-16|2001-12-20|Bristol-Myers Squibb Company|Hiv integrase inhibitors|
    ES2213485B1|2003-02-13|2005-12-16|Almirall Prodesfarma, S.A.|DERIVATIVES OF 2-FENILPIRAN-4-ONA.|
    US8598086B2|2009-06-08|2013-12-03|Dow Agrosciences, Llc.|3-halo--4-iminotetrahydropicolinates and their use as herbicides|
    US8252938B2|2009-06-08|2012-08-28|Dow Agrosciences, Llc.|Process for the preparation of 6--4-aminopicolinates|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB7912062|1979-04-05|
    [返回顶部]